Antigenicity study of nonspecific immunostimulator BARODON®
Korean Journal of Veterinary Research 2003, 43(2): 255-261
Eun-Hye Jo, Sung-Dae Cho, Nam-Shik Ahn, Ji-Won Jung, Se-Ran Yang, Joon-Suk Park, Ki-Su Park, Min-Su Seo, In-Sun Hong, Eun-Hye Jo, Nguyen Ba Tiep, Yong-Soon Lee, Kyung-Sun Kang.
The antigenicity of nonspecific immunostimulator BARODON®, a newly developed drug, was investigated by tests for passive cutaneous anaphylaxis (PCA) and active systemic anaphylaxis (ASA) in mice and guinea pigs. In ASA test using guinea pigs, there were no significant clinical symptoms in all individuals of low (0.3%) and high (3%) doses of both groups treated with only BARODON® and cotreated with BARODON® and adjuvant group. In PCA test, blue spots of Evan's were observed from 26 to 210 in homologous group and from 22 to 25 dilution rate in heterologous group of BSA treated positive control group. However, intradermal sensitization with antiserum obtained from low (0.3%) and high (3%) dose of BARODON® only treatment group and treated-with-adjuvant group, followed by intravenous injection of respective antigen and Evan's blue mixture (1:1) showed no blue spot observed.
In conclusion, BARODON®, as shown in ASA and PCA tests, did not cause anaphylatic shock when treated 3 and 10 times higher than clinically intended dose, nor induce IgE, so that might not have antigenic properties in mice and guinea pigs.
